Baby Detect : Genomic Newborn Screening
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Jan 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Baby Detect trial is studying a new way to screen newborns for serious genetic conditions that can be treated early. By using a simple blood test from babies within their first 28 days of life, the program aims to identify 126 different genetic disorders linked to 361 specific genes. This early detection can help doctors start treatment right away, which can prevent severe health issues and improve the baby's quality of life.
To participate in this study, babies must be between birth and 28 days old, and their parents need to give consent. The blood samples will be collected during this time and analyzed for the targeted conditions. This trial is currently recruiting participants, and it includes all newborns, regardless of gender. If your baby is eligible, this could be an important opportunity to help identify and address potential health issues right from the start.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • newborn between birth and 28 days of life
- • consent of parent
- Exclusion Criteria:
- • + 28 days
- • Non consent of parent
About Centre Hospitalier Universitaire De Liege
The Centre Hospitalier Universitaire de Liège (CHU Liège) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, CHU Liège integrates cutting-edge scientific inquiry with clinical practice, fostering an environment that enhances the development of new therapies and medical interventions. With a multidisciplinary team of experienced researchers and healthcare professionals, the institution is dedicated to improving patient outcomes and contributing to the global body of medical knowledge. CHU Liège emphasizes collaboration with industry partners and academic institutions to drive excellence in clinical research and support the translation of findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liege, Wallonia, Belgium
Patients applied
Trial Officials
Laurent Servais
Principal Investigator
Centre Hospitalier Universitaire de Liege
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials